Oncology Venture A/S announced that an update of its ongoing clinical development of the PARP inhibitor, 2X-121, will be presented at an upcoming meeting in Boston on January 28-30th. Oncology Venture announced that an update of the company's ongoing clinical development of its proprietary PARP inhibitor 2X-121 "Titled: A novel drug specific multigene mRNA biomarker for the PARP/Tankyrase inhibitor 2X-121" has been accepted for poster presentation at the upcoming PARP & DDR Inhibitor Summit taking place in Boston on January 28th-30th, gathering VPs, Heads and Directors of Translational Oncology, Target Discovery, and Early Drug Development companies. The poster includes data from the use of a 2X-121 specific DRP® biomarker that the company has developed to enable the selection of patients most likely to respond to the drug. The company has chosen to publish this announcement now, even though the company is of the opinion that the contents of this announcement does not constitute information which will impact the company's share price. However, in the light of the recent events the company finds that expedited access to this information is relevant in order to provide the highest level of transparency for the members of the general public interested in the news flow from the company.